CRLF2 and neoplasm: Limitations of our study include an incomplete ability to assess potential on-target/off-tumor or off-target effects of ruxolitinib and TSLPRCART in immunocompromised mouse models, although immunohistochemical analyses in our original preclinical study detected weak or absent TSLPR staining of multiple normal tissues [35].